Lynparza (olaparib), a PARP inhibitor, before CRPC.

[pjoshea13]

Some hype over a new study [1]:

"Our data suggest that ADT can functionally impair HR {defects} prior to the development of castration resistance and that, this potentially could be exploited therapeutically using PARP inhibitors in combination with androgen-deprivation therapy upfront in advanced or high-risk prostate cancer."

The idea seems to be that PARP, a defect repair mechanism, is increasingly called upon during ADT, so there might be synergy between ADT & a PARP inhibitor such as Lynparza, well before CRPC emerges. More cell death up-front & a longer mean time to CRPC?

-Patrick

[1] nature.com/articles/s41467-...

The paper is open-access, i.e. full text. (Spoiler alert - it is heavy going.)

[Sisira]

Patrick,

This seems to be a useful finding. Are there any oncologists at present who have started using PARP inhibitors to counteract the the functional impairment of HR by the use of ADT?

Thanks for the information.

Sisira

[pjoshea13 in reply to Sisira]

Sisira,

I somehow doubt it. Perhaps when we see trial results?

I searched on <PARP prostate>:

clinicaltrials.gov/ct2/resu...

-Patrick

[vandy69]

Dr. Snuffy Myers prescribed Lynparza for me when a Guardant360 liquid biopsy revealed that my cancer had an ATM defect. It worked for me for about 9 months.

[Sisira in reply to vandy69]

Thank you for your response.

Sisira